Portal de Periódicos da CAPES

Controversies in the management of Irvine-Gass syndrome

2013; Volume: 44; Issue: 6 Linguagem: Inglês

10.3928/23258160-20131105-01

2325-8179

Daniel F. Kiernan, Seenu M. Hariprasad,

Ocular Diseases and Behçet’s Syndrome

Practical RetinaControversies in the management of Irvine-Gass syndrome Daniel F. Kiernan, MD, , and , MD Seenu M. Hariprasad, Daniel F. Kiernan, MD and Seenu M. Hariprasad Ophthalmic Surgery, Lasers and Imaging Retina, 2013;44(6):522–527Published Online:November 05, 2013https://doi.org/10.3928/23258160-20131105-01Cited by:5View Full TextPDF ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInRedditEmail SectionsMore1.Gass JDM, Norton EWD. Cystoid macular edema and papilledema following cataract extraction: a fluorescein funduscopic and angiographic study. Arch Ophthalmol. 1966; 76:646–662.10.1001/archopht.1966.03850010648005 Crossref MedlineGoogle Scholar2.Lee VH, Robinson JR. Topical ocular drug delivery: recent developments and future challenges. J Ocul Pharmacol. 1986; 2(1):67–108.10.1089/jop.1986.2.67 Crossref MedlineGoogle Scholar3.Idrees F, Vaideanu D, Fraser SG, Sowden JC, Khaw PT. A review of anterior segment dysgeneses. Surv Ophthalmol. 2006; 51(3):213–231.10.1016/j.survophthal.2006.02.006 Crossref MedlineGoogle Scholar4.Geroski DH, Edelhauser HF. Drug delivery for posterior segment eye disease. Invest Ophthalmol Vis Sci. 2000; 41(5):961–964. MedlineGoogle Scholar5.Sahoo SK, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov Today. 2008; 13(3–4):144–151.10.1016/j.drudis.2007.10.021 Crossref MedlineGoogle Scholar6.Hariprasad SM, Akduman L, Clever JA, Ober M, Recchia FM, Mieler WF. Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%. Clin Ophthalmol. 2009; 3:147–154.10.2147/OPTH.S4684 Crossref MedlineGoogle Scholar7.Genead MA, Fishman GA. Efficacy of sustained topical dorzolamide therapy for cystic macular lesions in patients with retinitis pigmentosa and usher syndrome. Arch Ophthalmol. 2010; 128(9):1146–1150.10.1001/archophthalmol.2010.172 Crossref MedlineGoogle Scholar8.Donnenfeld ED. Difluprednate for the prevention of ocular inflammation postsurgery: an update. Clin Ophthalmol. 2011; 5:811–816.10.2147/OPTH.S6541 Crossref MedlineGoogle Scholar9.Thach AB, Dugel PU, Flindall RJ, Sipperley JO, Sneed SR. A comparison of retrobulbar versus sub-Tenon's corticoste-roid therapy for cystoid macular edema refractory to topical medications. Ophthalmology. 1997; 104(12):2003–2008.10.1016/S0161-6420(97)30065-7 Crossref MedlineGoogle Scholar10.Spitzer MS, Ziemssen F, Yoeruek E, Petermeier K, Aisenbrey S, Szurman P. Efficacy of intravitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema. J Cataract Refract Surg. 2008; 34(1):70–75.10.1016/j.jcrs.2007.08.021 Crossref MedlineGoogle Scholar11.Boscia F, Furino C, Dammacco R, Ferreri P, Sborgia L, Sborgia C. Intravitreal triamcinolone acetonide in refractory pseudophakic cystoid macular edema: functional and anatomic results. Eur J Ophthalmol. 2005; 15(1):89–95. Crossref MedlineGoogle Scholar12.Koutsandrea C, Moschos MM, Brouzas D, Loukianou E, Apostolopoulos M, Moschos M. Intraocular triamcinolone acetonide for pseudophakic cystoid macular edema: optical coherence tomography and multifocal electroretinography study. Retina. 2007; 27(2):159–164.10.1097/IAE.0b013e31802e3e5c Crossref MedlineGoogle Scholar13.Wang K, Wang Y, Gao L, Li X, Li M, Guo J. Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Biol Pharm Bull. 2008; 31(8):1541–1546.10.1248/bpb.31.1541 Crossref MedlineGoogle Scholar14.Lowder C, Belfort R, Lightman S, et al.Ozurdex HURON Study Group. Dexamethasone intravitreal implant for non-infectious intermediate or posterior uveitis. Arch Ophthalmol. 2011; 129(5):545–553.10.1001/archophthalmol.2010.339 Crossref MedlineGoogle Scholar15.Dutra Medeiros M, Navarro R, Garcia-Arumí J, Mateo C, Corcóstegui B. Dexamethasone intravitreal implant for treatment of patients with recalcitrant macular edema resulting from Irvine-Gass syndrome. Invest Ophthalmol Vis Sci. 2013; 54(5):3320–3324.10.1167/iovs.12-11463 Crossref MedlineGoogle Scholar16.Kiernan DF, Donnenfeld ED, et al.A single 700 μg dexamethasone intravitreal implant (Ozurdex) effectively treats complex postoperative cystoid macular edema. Presented at: the Association for Research in Vision and Ophthalmology meeting, abstract 3274–A0125; May 2013; Seattle, WA. Google Scholar17.Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology. 2006; 113(9):1533–1538.10.1016/j.ophtha.2006.02.065 Crossref MedlineGoogle Scholar18.Stepien KE, Eaton AM, Jaffe GJ, Davis JL, Raja J, Feuer W. Increased incidence of sterile endophthalmitis after intravitreal triamcinolone acetonide in spring 2006. Retina. 2009; 29(2):207–213.10.1097/IAE.0b013e31818eccb3 Crossref MedlineGoogle Scholar Next article FiguresReferencesRelatedDetailsCited by Toffoletto N, Salema-Oom M, Anguiano Igea S, Alvarez-Lorenzo C, Saramago B and Serro A (2021) Drug-Loaded Hydrogels for Intraocular Lenses with Prophylactic Action against Pseudophakic Cystoid Macular Edema, Pharmaceutics, 10.3390/pharmaceutics13070976, 13:7, (976) Toffoletto N, Saramago B and Serro A (2020) Therapeutic Ophthalmic Lenses: A Review, Pharmaceutics, 10.3390/pharmaceutics13010036, 13:1, (36) Altintas A and Ilhan C (2019) Intravitreal Dexamethasone Implantation in Intravitreal Bevacizumab Treatment-resistant Pseudophakic Cystoid Macular Edema, Korean Journal of Ophthalmology, 10.3341/kjo.2018.0106, 33:3, (259), . AGK A (2018) Alternative treatment methods in eyes with pseudophakic cystoid macular edema, International Journal of Clinical and Experimental Ophthalmology, 10.29328/journal.ijceo.1001019, 2:2, (032-038) Altintas A (2018) The management of Irvine-Gass Syndrome in a patient using Inhaler Steroid, International Journal of Clinical and Experimental Ophthalmology, 10.29328/journal.ijceo.1001011, (001-005) Request Permissions InformationCopyright 2013, SLACK IncorporatedPDF download • 364 KBDaniel F. Kiernan, MD, can be reached at Ophthalmic Consultants of Long Island, 2000 N. Village Ave., Rockville Centre, NY 11570; 516-766-2519; email: [email protected]com.Seenu M. Hariprasad, MD, can be reached at the Department of Ophthalmology and Visual Science, University of Chicago, 5841 S. Maryland Avenue, MC2114, Chicago, IL 60637; 773-795-1326; email: [email protected]edu.Disclosures: Dr. Kiernan is a consultant for, is on the speakers' bureau for, and/or owns stock in Allergan, Regeneron, Alimera, Bayer, Ocular Therapeutix, Physician Recommended Nutriceuticals (PRN), Thrombo-Genics, Lpath Inc., and Akron Inc. Dr. Hariprasad is a consultant or on the speakers' bureau for Regeneron, Takeda, Alcon, Allergan, Bayer, Optos, Ocular Therapeutix, and OD-OS. Published online11/05/13